• 

• 1 / 6

Citi on ONGC | A current spike in crude costs retains sentiment optimistic for now for ONGC, stated Citi. Sentiment might rapidly reverse if and when crude costs come off, the brokerage agency added whereas sustaining its ‘promote’ advice.

• 

• 2 / 6

Jefferies on Divi’s Laboratories | The corporate’s inventory is buying and selling at a 32 p.c premium to Gland and different large-cap contract producers, Jefferies stated sustaining its ‘maintain’ ranking on Divi’s Lab shares.

• 

• 3 / 6

Kotak Institutional Equities on Divi’s Lab | Valuations adequately seize the corporate’s development narrative from a medium-term perspective, stated Kotak Equities. The brokerage agency has retained its ‘cut back’ advice on the inventory.

• 

• 4 / 6

CLSA on Apollo Hospitals | Fundraise in Apollo HealthCo is a key catalyst for vital upside hereon, believes CLSA. Nevertheless, the brokerage agency has reduce FY22-24 EBITDA by 3-5 p.c on decrease margin assumptions for pharmacy.

• 

• 5 / 6

Citi on Persistent Programs | The acquisition of Knowledge Glove Property is predicted to dilute EBIT margin by 75 foundation factors in FY23, stated Citi sustaining its ‘promote’ name on the corporate’s inventory.

• 

• 6 / 6

CLSA on Muthoot Finance | CLSA has downgraded its ranking on shares of Muthoot Finance to ‘outperform’ and has reduce EPS estimates by 3-9 p.c as larger public sale spoils the celebration.